MARKET WIRE NEWS

Subscribe to Our Newsletter

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

MWN-AI** Summary

Rezolute, Inc. (Nasdaq: RZLT), a biotechnology company focused on treating refractory hypoglycemia caused by hyperinsulinism (HI), announced a significant development regarding its investigational therapy, ersodetug. Following a preliminary review of data from the Phase 3 sunRIZE study, the U.S. Food and Drug Administration (FDA) has recommended a pre-BLA (Biologics License Application) meeting, signaling a potential pathway for the company to seek regulatory approval for treating congenital HI.

The sunRIZE study, which aimed to assess the safety and efficacy of ersodetug in individuals with congenital HI, showed glycemic improvements, although it did not meet its primary endpoint regarding hypoglycemia events monitored by glucose testing. Notably, secondary endpoints based on continuous glucose monitoring (CGM) indicated clinically relevant improvements. In March 2026, Rezolute discussed trial challenges with the FDA, specifically the complexities of measuring hypoglycemia in this patient population. The FDA encouraged the company to compile additional CGM data for independent review.

Despite the challenges faced in meeting primary outcomes, the Agency’s recommendation for a pre-BLA meeting signifies a willingness to pursue a thorough evaluation based on the entire body of clinical data. This meeting represents an opportunity for Rezolute to discuss further development plans, especially in light of forthcoming topline results from the upLIFT study focusing on tumor HI.

Rezolute’s CEO, Nevan Charles Elam, expressed appreciation for the FDA's in-depth review and commitment to addressing the needs of individuals suffering from rare diseases like congenital HI. Julie Raskin, CEO of Congenital Hyperinsulinism International, echoed similar sentiments, highlighting the unmet needs for effective treatment options in this community. The ongoing open-label extension of the sunRIZE study suggests ongoing patient engagement and potential clinical benefits of ersodetug over extended use.

MWN-AI** Analysis

Rezolute, Inc. (Nasdaq: RZLT) has recently gained the FDA's recommendation for a pre-Biologics License Application (BLA) meeting concerning ersodetug, its investigational treatment for congenital hyperinsulinism (HI). While the Phase 3 sunRIZE trial did not meet primary endpoints, the FDA's invitation signals a potential pathway for approval based on continuous glucose monitoring data. This development indicates the agency's recognition of the unmet needs within rare disease communities, which may bode well for Rezolute’s long-term prospects.

Investors should consider this pivotal moment, as the company prepares to report topline results from its Phase 3 upLIFT study in tumor-related HI this quarter. Positive results from this study could bolster confidence in the therapeutic efficacy of ersodetug and expand its submission strategy across both conditions. Moreover, the ongoing open-label extension of the sunRIZE trial, demonstrating sustained patient retention and positive glycemic control over extended treatment durations, may enhance Rezolute’s narrative and value proposition.

However, caution is warranted. The FDA has not guaranteed approval and may still require additional clinical data post-review. Should Rezolute face challenges in demonstrating clinical efficacy, particularly for congenital HI, it could impede the viability of ersodetug and affect the stock’s performance.

Given the inherent volatility in biotechnology stocks, along with the uncertainties around the BLA process, investors may want to adopt a watchful approach. Monitoring the outcomes of the upcoming upLIFT results and any further communications from the FDA will be critical. Continued collaboration with regulatory bodies and stakeholders can bolster Rezolute's standing, but investors should remain cognizant of the risks associated with the development timelines and FDA’s regulatory landscape.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities 

On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the U.S. Food and Drug Administration (“FDA” or “Agency”) recommended a pre-BLA meeting with the Company as a precursor to submitting a BLA.

As previously reported, sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, demonstrated glycemic improvements, but did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose (SMBG) were not statistically significant compared to placebo. Although the key secondary endpoint of time in hypoglycemia by continuous glucose monitoring (CGM) was not met in the Week 24 End-of-Treatment evaluable window, consistent and clinically relevant improvements in hypoglycemia were observed for this and multiple other CGM-based hypoglycemia endpoints in both treatment arms.

At a March 2026 Type B meeting with FDA, the Agency acknowledged the challenges posed by behavioral factors in clinical trials in this patient population, including limitations associated with SMBG based measures of hypoglycemia. At the meeting, the Agency requested that the Company provide the continuous CGM data for its independent review. In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.

The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.

In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.

“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We share FDA’s commitment to addressing the significant unmet needs of individuals living with rare diseases like congenital HI, where traditional drug development can present unique challenges. We believe this unusual process of preliminary review of detailed data demonstrates what can be achieved when regulators, companies, clinicians, and advocacy organizations work collaboratively to evaluate the totality of evidence for promising rare disease therapies.”

“For many people living with congenital hyperinsulinism, the threat of severe and unpredictable hypoglycemia remains a daily reality, and existing treatments are not enough,” said Julie Raskin, Chief Executive Officer of Congenital Hyperinsulinism International (CHI). “We are encouraged by the progress toward potential new therapies and grateful to the patients, families, researchers, clinicians, regulators, and biotechnology companies working together to bring better options to our community.”

The open-label extension (OLE) phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE ranging from approximately nine months to well over two years. This, along with continued glycemic control and a notable reduction in the use of background standard of care therapies, potentially indicate continued glycemic and clinical benefit with ersodetug in longer-term use.

About Ersodetug 

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.

About Rezolute, Inc. 

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Forward-Looking Statements  

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the overall BLA process, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, despite the FDA encouraging us to request a pre-BLA meeting for congenital HI, there can be no assurance that FDA will agree with the Company that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support the approval for ersodetug in congenital HI. Accordingly, FDA may determine that additional clinical data, including data from a new randomized controlled trial similar to sunRIZE, are required to support approval. Should the Agency make such a determination, it would adversely impact the timing and feasibility of approval for the congenital HI indication as well as the the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. 

Contacts: 

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cmkim@rezolutebio.com
336-608-9706


FAQ**

What are the implications for Rezolute Inc. (RZLT) if the FDA determines that additional clinical data is required for the approval of ersodetug for congenital HI, as indicated during their recent meeting?
If the FDA requires additional clinical data for Rezolute Inc.'s ersodetug for congenital HI, it could delay approval and commercialization, potentially impacting the company's financial outlook and stock performance negatively.
How will the topline results from the upLIFT study in tumor HI impact the overall BLA submission strategy for Rezolute Inc. (RZLT) for both congenital and tumor HI indications?
The topline results from the upLIFT study in tumor HI will significantly influence Rezolute Inc.'s BLA submission strategy by potentially strengthening the evidence for both congenital and tumor HI indications, positioning them for a more robust regulatory review.
Given the challenges outlined by the FDA regarding behavioral factors in clinical trials for congenital HI, what steps is Rezolute Inc. (RZLT) taking to address these challenges moving forward?
Rezolute Inc. is implementing comprehensive strategies to enhance patient engagement and adherence in clinical trials for congenital hyperinsulinism, including the use of innovative technology and patient education programs to mitigate behavioral challenges as per FDA guidance.
What potential advantages does ersodetug offer over existing treatments for hyperinsulinism according to the data from the ongoing sunRIZE study and the ongoing open-label extension phase at Rezolute Inc. (RZLT)?
Ersodetug may provide enhanced glycemic control and reduced hypoglycemic events compared to existing treatments for hyperinsulinism, as indicated by promising data from the ongoing sunRIZE study and its open-label extension at Rezolute Inc. (RZLT).

**MWN-AI FAQ is based on asking OpenAI questions about Rezolute Inc. (NASDAQ: RZLT).

Rezolute Inc.

NASDAQ: RZLT

RZLT Trading

-6.37% G/L:

$3.675 Last:

5,049,918 Volume:

$4.56 Open:

iqst Ad 300

RZLT Latest News

$291,628,088
79,022,403
1.3%
35
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City

Check Your Online Brokerage For RZLT

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News